Skip Navigation

About Neornat

CEO Message

대표이사 사진

NEORNAT Inc. is a company that researches the role and function of RNA in the occurrence and metastasis of cancer, identifies new anticancer mechanisms, and researches and develops RNA-based anticancer drugs that target it.

For a long time, RNA has been attracting attention only for its role in transcribing proteins in vivo based on DNA, but recently, it has been reported that numerous non-coding RNAs that are not involved in protein transcription have a meaningful effect on the editing or expression of other genes. We aim to become a leading company in the development of RNA therapeutics that selectively target RNA or RNA network control mechanisms for diseases, particularly cancer, with high-level research as the source technology. The main research areas are macrophage immuno-oncology drugs, which have not been identified so far, and RNA regulator-targeted anti-cancer drugs. In addition, we are developing a diagnostic kit that enables early liver cancer treatment by discovering the world's first whole-cycle liver disease diagnostic multiple markers using big data-based liver cancer diagnosis technology that we have built for many years, enabling early liver cancer diagnosis.

With these efforts and achievements, NEORNAT Inc. promises to contribute to human health and quality of life.

NEORNAT Inc. CEO Suk Woo Nam

Company Identity

NEORNAT Inc. is a company that researches and develops first-in-class anticancer drugs that target RNA regulators.

네오나 네오나
NEORNAT
=
Neo (The New)
+
RNA + T (Therapy)
  • The New RNA Therapeutics Company
  • First-in-Class Target Therapeutics

History

2023

  • 01

    Published an article on Experimental & Molecular Medicine (IF: 12.153) : ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer

2022

  • 11

    Selected as Korea Angel Investment TIPS

  • 09

    Established R&D Center (located in Banpo-dong, Seocho-gu)

  • 06

    Steintech Bio Season 1, Final Round Top 5 Selection and Best Company Selection
    Published an article on Experimental & Molecular Medicine (IF: 12.153) : hnRNPC induces isoform shifts in miR-21-5p leading to cancer development

  • 03

    Completed pre-round Series A investment

2021

  • 12

    Signed out of license out with KPS Co., Ltd. for liver cancer diagnosis/analysis technology
    Catholic University Industry-University Cooperation Foundation- NEORNAT Inc. transfers 3 technologies for new drug development

  • 08

    Published in Oncogene (IF:9.867) paper

  • 07

    Selected as Korea Angel Investment TIPS

  • 04

    Selected as a 3-year project for the disease-centered translational research project

  • 01

    Shinhan Capital Investment Attraction

2020

  • 11

    Catholic University Industry-University Cooperation Foundation - Completed technology transfer for 4 cases of NEORNAT Inc.

  • 10

    Selected as K-BIC STAR (New drug development start-up company, Korea Health Industry Promotion Agency)

  • 09

    Completed attracting angel investment
    Established NEORNAT Inc.

People

CEO Suk Woo Nam

  • Professor, Dept of Pathology, College of Medicine,
    The Catholic Univ. of Korea
  • Director, Functional RNomics Research Center (FRRC),
    The Catholic Univ. of Korea
  • Associate Editor, Biomolecules
  • Advisory Editorial Board, Molecular & Cellular Toxicology
  • Advisory Editorial Board, Archives of Pharmacal Research
  • Member, American Associate for Cancer Research
  • Member, National Academy of Medicine of Korea
  • Member, The Korean Cancer Association
  • Member, The Pharmaceutical Society of Korea
  • Member, Korea Genome Organization

CSO&CDD Ki Ho Moon

  • 30 years of pharmaceutical industry experience
    (New drug research, Clinical development, Marketing)
  • Graduated from the Department of Pharmacy and Graduate School of Pharmacy, Sungkyunkwan University

Leader Hee Doo Yang

  • Lab of Cancer RNA Biology
  • Ph.D. in Tumor Cell Biology, The Catholic University, South Korea
  • Specialty: RNA variation and functional study in tumor immunity
  • SCI paper: 11, Patent: 5

Leader Sang Yean Kim

  • Lab of Cancer RNA Biology
  • Ph.D. in Tumor Cell Biology, The Catholic University, South Korea
  • Specialty: cancer RNA variation and functional study
  • SCI paper: 7, Patent: 3

Leader Jung Hwan Yoon

  • Research Lecturer, The Department of Pathology, The Catholic University, South Korea
  • Ph.D. in Tumor Cell Biology, The Catholic University, South Korea
  • Specialty: Carcinogenesis and progression mechanism study in gastric cancer
  • SCI paper: 50, Patent: 13

Collaborator

Domestic

  • KPS
  • cellArtgen
  • BioNeer
  • 위 특허법률사무소
  • 법무법인 디라이트

Overseas

  • WuXi AppTec
  • Debiopharm
  • algokbio

Contact us

Headquarter

  • Address

    #5104, Catholic Omnibus Park Building A, The Catholic Univ. of Korea Banpo-daero 222, Secho-gu, Seoul (06591)

  • TEL

    02-2258-7308

  • FAX

    02-537-6586

Research center

  • Address

    2F, 47-3, Banpo-daero 39-gil, Seocho-gu, Seoul (06579)

  • TEL

    02-595-2812

  • FAX

    02-595-2810